Both PD-L1+TILs and TILs were changed in pre- and post-NAT samples of HER2-positive breast cancer, suggesting that the immune microenvironment has a crucial role in neoadjuvant treatment. The gene discussed is ERBB2; the disease is breast carcinoma.